Species-Specific Urothelial Toxicity with an anti-HIV Non-Catalytic Site Integrase Inhibitor (NCINI) is Related to Unusual pH-Dependent Physicochemical Changes

GS-9695 and GS-9822 are subsequent technology Non-Catalytic Website Integrase Inhibitors (NCINIs) with considerably improved efficiency towards HIV in contrast with earlier medication equivalent to BI-224436. Improvement stopped because of vacuolation of the bladder urothelium seen in cynomolgus monkey however not in rat; this lesion was absent in equal preclinical research with BI-224436 (examined in canine and rat).
Lesions had been unlikely to be attributable to focus on since NCINIs particularly goal viral integrase protein and no mammalian homologue is thought. Secondary pharmacology research, mitochondrial toxicity research, immunophenotyping and evaluation of proteins implicated in cell-cell interactions and/or bladder integrity (e-cadherin, pan-cytokeratin, uroplakins) failed to supply any believable rationalization for the species-specificity of the lesion.
Because it was characterised by irritation and disruption of urothelial morphology, we investigated physicochemical adjustments within the bladder of cynomolgus monkey (urinary pH 5.5-7.4) which may not happen within the bladder of rats (urinary pH 7.3-8.5). In measurements of floor exercise, GS-9822 confirmed an uncommon transition from a monolayer to a bilayer on the air/water interface with reducing pH, attributed to the sturdy affiliation between drug molecules in adjoining bilayer leaflets and anticipated to be extremely disruptive to the urothelium.
Structural evaluation of GS-9822 and GS-9695 confirmed zwitterionic traits over the vary of pH anticipated in cynomolgus monkey however not rat urine. This unique floor behaviour is unlikely with BI-224436 since it could transition from impartial to cationic (by no means zwitterionic) with reducing pH. These knowledge present helpful insights to information discovery and growth of NCINIs, associated compounds and zwitterions.

A serine protease inhibitor camostat mesilate prevents podocyte apoptosis and attenuates podocyte damage in metabolic syndrome mannequin rats

Metabolic syndrome (MetS) is related to continual kidney illness and proteinuria. Beforehand, we reported {that a} artificial serine protease inhibitor, camostat mesilate (CM), mitigated hypertension and proteinuria in rodent illness fashions. The current examine evaluated the anti-hypertensive and anti-proteinuric results of CM in MetS mannequin rats (SHR/ND mcr-cp). Rats had been divided into regular salt-fed (NS), excessive salt-fed (HS), HS and CM-treated (CM), and HS and hydralazine-treated (Hyd) teams. Rats had been sacrificed after 4 weeks of remedy. Extreme hypertension and proteinuria had been noticed within the HS group.
Though CM and Hyd equally alleviated hypertension, CM suppressed proteinuria and glomerular sclerosis extra effectively than Hyd. The HS group revealed a lower in podocyte quantity and podocyte-specific molecules, along with a rise in glomerular apoptotic cells and apoptosis-related proteins within the kidney. These adjustments had been considerably attenuated by CM, however not by Hyd.
Moreover, CM ameliorated the apoptotic alerts in murine cultured podocytes stimulated with the excessive glucose and aldosterone medium. In conclusion, CM may exert renoprotective results in MetS mannequin rats, along with the inhibition of podocyte apoptosis. Our examine means that serine protease inhibition might turn into a brand new therapeutic technique towards MetS-related hypertension and renal accidents.

Efficacy and security of TAS-115, a novel oral multi-kinase inhibitor, in osteosarcoma: an enlargement cohort of a section I examine

Background osteosarcoma is a uncommon, main malignant bone tumour with restricted out there remedies for superior or recurrent illness, leading to a poor prognosis for sufferers. TAS-115 is a novel tyrosine kinase inhibitor beneath investigation in a section I examine in sufferers with strong tumours. We report knowledge of osteosarcoma sufferers within the enlargement cohort of this ongoing examine.
Sufferers and strategies an evaluation of this multicentre, open-label examine was carried out 6 months after the ultimate affected person was enrolled, and included sufferers aged ≥15 years, with unresectable or recurrent osteosarcoma, and who had refractory to straightforward remedy or for whom no customary remedy was out there. TAS-115 650 mg/day was orally administered in a 5 days on/2 days off schedule.
 Species-Specific Urothelial Toxicity with an anti-HIV Non-Catalytic Site Integrase Inhibitor (NCINI) is Related to Unusual pH-Dependent Physicochemical ChangesOutcomes a complete of 20 sufferers with osteosarcoma had been enrolled. The most typical antagonistic drug reactions (ADRs) had been neutrophil depend decreased (75%), aspartate aminotransferase elevated (50%), and platelet depend decreased (50%); 85% of sufferers had grade ≥ Three ADRs. Lengthy-term illness management (>1 yr) with TAS-115 was achieved in three sufferers. One of the best general response was steady illness (50%); no affected person achieved an entire or partial response.
Median progression-free survival was Three months; 4-month and 12-month progression-free charges had been 42% and 31%, respectively. Conclusion the protection and tolerability of TAS-115 and long-term illness stability for sufferers with unresectable or recurrent osteosarcoma had been confirmed on this examine, suggesting that TAS-115 is a promising novel remedy for superior osteosarcoma sufferers. Trial registration quantity: JapicCTI-132333 (registered on November 8, 2013).

Inhibitory neurons within the superior colliculus mediate number of spatially-directed actions

Choice making is a cognitive course of that mediates behaviors essential for survival. Selecting spatial targets is an experimentally-tractable type of resolution making that will depend on the midbrain superior colliculus (SC). Whereas physiological and computational research have uncovered the practical topographic group of the SC, the position of particular SC cell varieties in spatial selection is unknown. Right here, we leveraged conduct, optogenetics, neural recordings and modeling to straight look at the contribution of GABAergic SC neurons to the number of opposing spatial targets.

Wnt agonist 1

B6059-200 200 mg
EUR 751
Description: Wnt agonist 1 is a small-molecule agonist of Wnt signaling pathway. The Wnt signaling pathway is an important signal transduction pathway that involved in a variety of physiological and pathological processes by regulating genes involved in cellular adhesion, proliferation, and differentiation.

Wnt agonist 1

B6059-5.1 10 mM (in 1mL DMSO)
EUR 108
Description: Wnt agonist 1 is a small-molecule agonist of Wnt signaling pathway. The Wnt signaling pathway is an important signal transduction pathway that involved in a variety of physiological and pathological processes by regulating genes involved in cellular adhesion, proliferation, and differentiation.

Wnt agonist 1

B6059-50 50 mg
EUR 357
Description: Wnt agonist 1 is a small-molecule agonist of Wnt signaling pathway. The Wnt signaling pathway is an important signal transduction pathway that involved in a variety of physiological and pathological processes by regulating genes involved in cellular adhesion, proliferation, and differentiation.

Wnt-6 Antibody

3570-100
EUR 316

Wnt-6 Antibody

3570-30T
EUR 146

Wnt-1 Antibody

3571-100
EUR 316

Wnt-1 Antibody

3571-30T
EUR 146

Wnt-2 Antibody

3572R-100
EUR 354

Wnt-2 Antibody

3572R-30T
EUR 146

Wnt-4 Antibody

3574R-100
EUR 316

Wnt-4 Antibody

3574R-30T
EUR 146

Wnt-1 Antibody

5754-100
EUR 316

Wnt-1 Antibody

5754-30T
EUR 146

Wnt-2 Antibody

6671-100
EUR 338

Wnt-2 Antibody

6671-30T
EUR 146

Wnt Antagonist, C59

2063-1
EUR 137

Wnt Antagonist, C59

2063-5
EUR 359

Wnt 6 antibody

20R-1649 100 ug
EUR 673
Description: Rabbit polyclonal Wnt 6 antibody

Wnt 2 antibody

20R-1650 100 ug
EUR 673
Description: Rabbit polyclonal Wnt 2 antibody

Wnt 4 antibody

20R-1651 100 ug
EUR 673
Description: Rabbit polyclonal Wnt 4 antibody

WNT-11 ELISA Kit| Mouse WNT-11 ELISA Kit

EF012834 96 Tests
EUR 689

Wnt-1 Polyclonal Antibody

ES3706-50ul 50ul
EUR 207
Description: A Rabbit Polyclonal antibody against Wnt-1 from Human/Mouse. This antibody is tested and validated for WB, ELISA, IHC, IF, WB, ELISA

Wnt-16 Polyclonal Antibody

ES3836-50ul 50ul
EUR 207
Description: A Rabbit Polyclonal antibody against Wnt-16 from Human/Mouse/Rat. This antibody is tested and validated for WB, ELISA, WB, ELISA

Wnt-1 Polyclonal Antibody

ES3706-100ul 100ul
EUR 279
Description: A Rabbit Polyclonal antibody against Wnt-1 from Human/Mouse. This antibody is tested and validated for WB, ELISA, IHC, IF, WB, ELISA

Wnt-16 Polyclonal Antibody

ES3836-100ul 100ul
EUR 279
Description: A Rabbit Polyclonal antibody against Wnt-16 from Human/Mouse/Rat. This antibody is tested and validated for WB, ELISA, WB, ELISA

Protein Wnt-3a Antibody

20-abx137444
  • EUR 704.00
  • EUR 328.00
  • EUR 230.00
  • 100 ug
  • 20 ug
  • 5 ug

Wnt-1 Polyclonal Antibody

ABP52707-003ml 0.03ml
EUR 158
Description: A polyclonal antibody for detection of Wnt-1 from Human, Mouse. This Wnt-1 antibody is for WB, IHC-P, IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the C-terminal region of human Wnt-1 at AA range: 270-350

Wnt-1 Polyclonal Antibody

ABP52707-01ml 0.1ml
EUR 289
Description: A polyclonal antibody for detection of Wnt-1 from Human, Mouse. This Wnt-1 antibody is for WB, IHC-P, IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the C-terminal region of human Wnt-1 at AA range: 270-350

Wnt-1 Polyclonal Antibody

ABP52707-02ml 0.2ml
EUR 414
Description: A polyclonal antibody for detection of Wnt-1 from Human, Mouse. This Wnt-1 antibody is for WB, IHC-P, IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the C-terminal region of human Wnt-1 at AA range: 270-350

Wnt-16 Polyclonal Antibody

ABP52837-003ml 0.03ml
EUR 158
Description: A polyclonal antibody for detection of Wnt-16 from Human, Mouse, Rat. This Wnt-16 antibody is for WB, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the Internal region of human Wnt-16

Wnt-16 Polyclonal Antibody

ABP52837-01ml 0.1ml
EUR 289
Description: A polyclonal antibody for detection of Wnt-16 from Human, Mouse, Rat. This Wnt-16 antibody is for WB, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the Internal region of human Wnt-16

Wnt-16 Polyclonal Antibody

ABP52837-02ml 0.2ml
EUR 414
Description: A polyclonal antibody for detection of Wnt-16 from Human, Mouse, Rat. This Wnt-16 antibody is for WB, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the Internal region of human Wnt-16

Protein Wnt-3a Antibody

20-abx110152
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Anti-Wnt-1 antibody

STJ98451 100 µl
EUR 234
Description: Mouse monoclonal to Wnt-1.

Anti-Wnt-10b antibody

STJ98452 100 µl
EUR 234
Description: Mouse monoclonal to Wnt-10b.

Anti-Wnt-5a antibody

STJ98453 100 µl
EUR 234
Description: Mouse monoclonal to Wnt-5a.

Anti-Wnt-5a antibody

STJ98454 100 µl
EUR 234
Description: Mouse monoclonal to Wnt-5a.

Anti-Wnt-1 antibody

STJ96272 200 µl
EUR 197
Description: Rabbit polyclonal to Wnt-1.

Anti-Wnt-16 antibody

STJ96471 200 µl
EUR 197
Description: Rabbit polyclonal to Wnt-16.

Wnt-1 Polyclonal Antibody

41535-100ul 100ul
EUR 252

Wnt-1 Polyclonal Antibody

41535-50ul 50ul
EUR 187

L Wnt-3A cells

S0011001 One Frozen vial
EUR 455

Polyclonal Wnt-6 Antibody

APR00134G 0.1mg
EUR 484
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human Wnt-6 . This antibody is tested and proven to work in the following applications:

Polyclonal Wnt-1 Antibody

APR00135G 0.1mg
EUR 484
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human Wnt-1 . This antibody is tested and proven to work in the following applications:

Polyclonal Wnt-2 Antibody

APR00136G 0.1mg
EUR 484
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human Wnt-2 . This antibody is tested and proven to work in the following applications:

Polyclonal Wnt-4 Antibody

APR00137G 0.1mg
EUR 484
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human Wnt-4 . This antibody is tested and proven to work in the following applications:

Polyclonal Wnt-1 Antibody

APR00320G 0.1mg
EUR 484
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human Wnt-1 . This antibody is tested and proven to work in the following applications:

Polyclonal Wnt-2 Antibody

APR00346G 0.1ml
EUR 484
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human Wnt-2 . This antibody is tested and proven to work in the following applications:

Wnt-3a GMP, CF

PR15121CF 10 ug
EUR 649

Wnt-6 Blocking Peptide

3570BP-50
EUR 153

Wnt-1 Blocking Peptide

3571BP-50
EUR 153

Wnt-2 Blocking Peptide

3572RBP-50
EUR 153

Wnt-4 Blocking Peptide

3574BP-50
EUR 153

WNT-1, human recombinant

4754-10
EUR 283

WNT-1, human recombinant

4754-1000
EUR 5705

WNT-1, human recombinant

4754-50
EUR 729

Wnt-2, human recombinant

7599-10
EUR 387

Wnt-2, human recombinant

7599-1000
EUR 7988

Wnt-2, human recombinant

7599-50
EUR 1186

EZSolution? Wnt Antagonist, C59

9493-1
EUR 137

WNT-3a, Human Recombinant

P1194-100
EUR 615

WNT-3a, Human Recombinant

P1194-20
EUR 196

WNT-7a, Human Recombinant

P1195-100
EUR 588

WNT-7a, Human Recombinant

P1195-20
EUR 185

pcDNA3.1(+)-Wnt-10a Plasmid

PVTB00127-2a 2 ug
EUR 356

Wnt 6 Blocking Peptide

33R-10508 50 ug
EUR 349
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of Wnt 6 antibody, catalog no. 20R-1649

Wnt 2 Blocking Peptide

33R-10509 50 ug
EUR 349
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of Wnt 2 antibody, catalog no. 20R-1650

Wnt 4 Blocking Peptide

33R-10510 50 ug
EUR 349
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of Wnt 4 antibody, catalog no. 20R-1651

Wnt-1 Recombinant Protein

40-216-0002mg 0.002 mg
EUR 259.25
Description: Wnt-1 is a secreted protein that signals through the Frizzled family of cell surface receptors and is required for normal embryonic development. Wnt-1 activation induces a complex signaling cascade that ultimately leads to the increased expression of over fifty genes. An important component of Wnt-1 signaling is the stabilization, and resulting accumulation, of the intracellular signaling protein, beta-catenin. Wnt signaling induces and maintains the transformed phenotype and, in certain embryonic cell lines, supports self renewal in the absence of significant differentiation. Elevated levels of Wnt proteins are associated with tumorigenesis and are present in numerous human breast cancers. Mature human Wnt-1 is a glycosylated protein containing 343 amino acid residues. Recombinant human Wnt-1 is a 38.4 kDa, non-glycosylated protein containing 343 amino acid residues.

Wnt-1 Recombinant Protein

40-216-001mg 0.01 mg
EUR 364.25
Description: Wnt-1 is a secreted protein that signals through the Frizzled family of cell surface receptors and is required for normal embryonic development. Wnt-1 activation induces a complex signaling cascade that ultimately leads to the increased expression of over fifty genes. An important component of Wnt-1 signaling is the stabilization, and resulting accumulation, of the intracellular signaling protein, beta-catenin. Wnt signaling induces and maintains the transformed phenotype and, in certain embryonic cell lines, supports self renewal in the absence of significant differentiation. Elevated levels of Wnt proteins are associated with tumorigenesis and are present in numerous human breast cancers. Mature human Wnt-1 is a glycosylated protein containing 343 amino acid residues. Recombinant human Wnt-1 is a 38.4 kDa, non-glycosylated protein containing 343 amino acid residues.

WNT-7A Recombinant Protein

40-577-0003mg 0.003 mg
EUR 259.25
Description: Wnt-7a belongs to the Wnt family of signaling proteins that play a key role in maintaining the integrity of embryonic and adult tissues. It is expressed in placenta, kidney, testis, uterus, fetal lung and fetal and adult brain. Most Wnt proteins can signal though a mechanism called the canonical Wnt pathway, in which Wnt proteins bind to and activate seven-pass transmembrane receptors of the Frizzled family ultimately leading to the disruption of β-Catenein degradation. Intracellular accumulation of β-Catenin increases translocation of the protein into the nucleus where it binds to TCF/LEF transcription factors and induces the expression of numerous genes. Increased Wnt/β-Catenein signaling is associated with tumorigenesis in a diverse set of human cancers. However, Wnt-7a/Frizzled-9 signaling has been shown to act as a tumor suppressor in non-small cell lung cancers. Recombinant human Wnt-7a is a 35.5 kDa glycoprotein containing 318 amino acids. Due to glycosylation, Wnt-7a migrates between 40-55 kDa by SDS-PAGE gel under unreduced conditions.

WNT-7A Recombinant Protein

40-577-0015mg 0.015 mg
EUR 364.25
Description: Wnt-7a belongs to the Wnt family of signaling proteins that play a key role in maintaining the integrity of embryonic and adult tissues. It is expressed in placenta, kidney, testis, uterus, fetal lung and fetal and adult brain. Most Wnt proteins can signal though a mechanism called the canonical Wnt pathway, in which Wnt proteins bind to and activate seven-pass transmembrane receptors of the Frizzled family ultimately leading to the disruption of β-Catenein degradation. Intracellular accumulation of β-Catenin increases translocation of the protein into the nucleus where it binds to TCF/LEF transcription factors and induces the expression of numerous genes. Increased Wnt/β-Catenein signaling is associated with tumorigenesis in a diverse set of human cancers. However, Wnt-7a/Frizzled-9 signaling has been shown to act as a tumor suppressor in non-small cell lung cancers. Recombinant human Wnt-7a is a 35.5 kDa glycoprotein containing 318 amino acids. Due to glycosylation, Wnt-7a migrates between 40-55 kDa by SDS-PAGE gel under unreduced conditions.

Wnt-9b Recombinant Protein

40-653 5 ug
EUR 259.25
Description: Formerly known as Wnt-15 or Wnt-14b, Wnt-9b is a secreted glycoprotein belonging to the Wnt family of signaling proteins that are critically involved in maintaining the integrity of both embryonic and adult tissues. Wnt-9b is primarily expressed in adult kidneys and during late embryogenesis, and shares with other Wnt family members the same highly conserved lipid-modified, cysteine-rich domain essential for cell signaling. As is true for most Wnt family members, Wnt-9b functions through the biochemical process known as the canonical Wnt pathway. In this process, Wnt proteins bind to and activate seven-pass transmembrane receptors of the Frizzled family, and ultimately results in the disruption of β-catenin degradation. Intracellular accumulation of β-catenin increases translocation of the protein into the nucleus, where it binds to TCF/LEF transcription factors to promote the expression of numerous genes. In this manner, Wnt signaling induces and maintains transformed phenotype, and, in certain embryonic cell lines, supports self-renewal in the absence of significant differentiation. While increased Wnt/β-catenin signaling is associated with tumorigenesis in a diverse set of human cancers, lack of Wnt signaling disrupts transcriptional activation of tumor suppressor genes, and has been shown to result in neoplastic transformation, oncogenesis, and human degenerative diseases. Altered Wnt-9b expression has been shown to result in the underdevelopment of the kidneys, and incomplete lip and cleft fusion in mice. Recombinant Human Wnt-9b is a monomeric glycoprotein containing 335 amino acid residues and has a calculated molecular weight of 36.9 kDa. Due to glycosylation, Recombinant Human Wnt-9b migrates at an apparent molecular weight of approximately 49-54 kDa by SDS-PAGE analysis under non-reducing conditions.

WNT-3A Recombinant Protein

40-700 2 ug
EUR 259.25
Description: Wnt-3a belongs to the Wnt family of signaling proteins that play a key role in maintaining the integrity of embryonic and adult tissues. Expression of Wnt-3a occurs primarily along the dorsal midline across overlapping regions of the Central Nervous System (CNS). Wnt-3a signaling is essential for various morphogenetic events, including embryonic patterning, cell determination, cell proliferation, CNS development, and cytoskeletal formation. Like other members of this family, Wnt-3a contains a highly conserved lipid-modified, cysteine-rich domain that is essential for cell signaling. During a biochemical process called the canonical Wnt pathway, Wnt family members bind to and activate, seven-pass transmembrane receptors of the Frizzled family, ultimately leading to the disruption of β-catenin degradation. Intracellular accumulation of β-catenin increases translocation of the protein into the nucleus, where it binds to TCF/LEF transcription factors to promote gene expression. Lack of Wnt signaling disrupts transcriptional activation of tumor suppressor genes, and has been shown to result in neoplastic transformation, oncogenesis, and human degenerative diseases. Recombinant Murine Wnt-3a is a monomeric glycoprotein containing 334 amino acid residues. Due to glycosylation, the Murine Wnt-3a migrates at an apparent molecular weight of approximately 38.0-41.0 kDa by SDS-PAGE analysis under non-reducing conditions.

Protein Wnt-10a (WNT10A) Antibody

20-abx301908
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Protein Wnt-4 (WNT4) Antibody

20-abx302751
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Recombinant Human WNT-1 Protein

PROTP04628 10ug
EUR 317
Description: Wnt-1 is a secreted protein that signals through the Frizzled family of cell surface receptors and is required for normal embryonic development. Wnt-1 activation induces a complex signaling cascade that ultimately leads to the increased expression of over fifty genes. An important component of Wnt-1 signaling is the stabilization, and resulting accumulation, of the intracellular signaling protein, β-catenin. Wnt signaling induces and maintains the transformed phenotype and, in certain embryonic cell lines, supports self renewal in the absence of significant differentiation. Elevated levels of Wnt proteins are associated with tumorigenesis and are present in numerous human breast cancers. Mature human Wnt-1 is a glycosylated protein containing 343 amino acid residues. Recombinant human Wnt-1 is a 38.4 kDa, non-glycosylated protein containing 343 amino acid residues.

Recombinant Human WNT-7A Protein

PROTO00755-1 15ug
EUR 317
Description: Wnt-7a belongs to the Wnt family of signaling proteins that play a key role in maintaining the integrity of embryonic and adult tissues. It is expressed in placenta, kidney, testis, uterus, fetal lung and fetal and adult brain. Most Wnt proteins can signal though a mechanism called the canonical Wnt pathway, in which Wnt proteins bind to and activate seven-pass transmembrane receptors of the Frizzled family ultimately leading to the disruption of β-Catenein degradation. Intracellular accumulation of β-Catenin increases translocation of the protein into the nucleus where it binds to TCF/LEF transcription factors and induces the expression of numerous genes. Increased Wnt/β-Catenein signaling is associated with tumorigenesis in a diverse set of human cancers. However, Wnt-7a/Frizzled-9 signaling has been shown to act as a tumor suppressor in non-small cell lung cancers. Recombinant human Wnt-7a is a 35.5 kDa glycoprotein containing 318 amino acids. Due to glycosylation, Wnt-7a migrates between 40-55 kDa by SDS-PAGE gel under unreduced conditions

Protein Wnt-2 (WNT2) Antibody

abx122394-100ug 100 ug
EUR 391

Protein Wnt-7b (WNT7B) Antibody

abx122911-100ug 100 ug
EUR 391

Protein Wnt-4 (WNT4) Antibody

20-abx116674
  • EUR 732.00
  • EUR 398.00
  • 150 ul
  • 50 ul

Protein Wnt-7a (WNT7A) Antibody

20-abx116675
  • EUR 732.00
  • EUR 398.00
  • 150 ul
  • 50 ul

Protein Wnt-3a (WNT3A) Antibody

abx117009-100ug 100 ug
EUR 467

Protein Wnt-5a (Wnt5a) Antibody

abx117221-100ug 100 ug
EUR 467

Protein Wnt-3a (WNT3A) Antibody

20-abx136135
  • EUR 495.00
  • EUR 704.00
  • EUR 356.00
  • 100 ul
  • 200 ul
  • 50 ul

Protein Wnt-5a (Wnt5a) Antibody

20-abx123422
  • EUR 592.00
  • EUR 857.00
  • EUR 411.00
  • 100 ul
  • 200 ul
  • 50 ul

Protein Wnt-6 (WNT6) Antibody

20-abx124423
  • EUR 411.00
  • EUR 592.00
  • 100 ul
  • 200 ul

Protein Wnt-3a Antibody (Biotin)

20-abx105841
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Protein Wnt-3a Antibody (FITC)

20-abx107257
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Protein Wnt-3a Antibody (HRP)

20-abx108677
  • EUR 411.00
  • EUR 1845.00
  • EUR 599.00
  • EUR 182.00
  • EUR 300.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Protein Wnt-4 (WNT4) Antibody

abx036970-100ug 100 ug
EUR 391

Protein Wnt-5a (WNT5A) Antibody

abx012361-100ul 100 ul
EUR 411
Though GABAergic SC neurons comprise a heterogeneous inhabitants with native and long-range projections, our outcomes display that GABAergic SC neurons don’t regionally suppress premotor output, suggesting that practical long-range inhibition as an alternative performs a dominant position in spatial selection. An attractor mannequin requiring solely intrinsic SC circuitry was adequate to account for our experimental observations. General, our examine elucidates the position of GABAergic SC neurons in spatial selection.

Leave a Reply

Your email address will not be published.